Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals will present a company overview at the Jefferies Global Healthcare Conference on November 18, 2026. The presentation is scheduled for 10:00 a.m. GMT and will be accessible via a live audio webcast. A replay will be available on the company's website shortly after the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alnylam management presents at Jefferies conference.
  • Webcast replay available for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Lead asset
ALN-4324
Phase 2 · Type 2 Diabetes Mellitus (T2DM)

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London. A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours a

Frequently Asked Questions

When will Alnylam present at the conference?

Alnylam will present on November 18, 2026, at 10:00 a.m. GMT.

Where can I watch the presentation?

The presentation will be available via a live audio webcast on Alnylam's website.

Will there be a replay of the presentation?

Yes, a replay will be posted on the website within 48 hours.

What is the Jefferies Global Healthcare Conference?

It is a prominent event for healthcare companies to present to investors.

ShareAdd on Google
Tags: ALNY Alnylam Pharmaceuticals Jefferies Conference RNAi therapeutics investor presentation healthcare conference
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$3587M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 2
Type 2 Diabetes Mellitus (T2DM) →

Catalyst track record

+13%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →